Nutra Pharma Corp. (NPHC) Stock Analysis

Nutra Pharma Corp. (NPHC) Healthcare & Pipeline Overview

Nutra Pharma Corp. operates in the specialty and generic drug manufacturing sector, focusing on pain management and neurological disorders. The company commercializes products like Nyloxin and Pet Pain-Away, targeting both human and animal markets with homeopathic and ethical drugs, primarily within the United States.

What Is the Investment Thesis for NPHC?

Nutra Pharma Corp. operates with a high profit margin of 1865.7% and a gross margin of 56.8%. The company's focus on niche markets like homeopathic pain relief for pets and specialized pain management products like Luxury Feet could provide growth opportunities. However, the company's OTC listing and small market capitalization present liquidity and transparency concerns. The success of their drug development pipeline, including RPI-78M and RPI-MN, is critical for long-term growth. Investors should closely monitor the company's ability to navigate the regulatory landscape and secure partnerships for commercializing its products.

Based on FMP financials and quantitative analysis

NPHC Key Highlights

Profit Margin of 1865.7% indicates high profitability on sales.

• Gross Margin of 56.8% suggests efficient cost management in product sales.
• P/E Ratio of 0.25 suggests the company may be undervalued relative to its earnings.
• Beta of -2.90 indicates the stock price moves inversely to the market, potentially offering diversification benefits.
• Focus on niche markets like homeopathic pain relief for pets and specialized pain management products like Luxury Feet.

Who Are NPHC's Competitors?

NPHC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are NPHC's Key Strengths?

Proprietary formulations for pain relief products.

• Focus on niche markets with limited competition.
• High profit margin of 1865.7%.
• Established brand recognition in specific product categories.

What Are NPHC's Weaknesses?

Small market capitalization and limited financial resources.

• OTC listing with associated liquidity and transparency concerns.
• Dependence on a limited number of products.
• Limited number of employees (4).

What Could Drive NPHC Stock Higher?

Clinical trial results for RPI-78M in treating neurological diseases could drive investor interest.

• Potential partnerships with pharmaceutical companies for expanded distribution.
• Expansion of the Nyloxin product line into new markets.
• Increasing sales of Pet Pain-Away in the growing pet healthcare market.
• Regulatory approvals for new indications of existing products.

What Are the Key Risks for NPHC?

Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.

• Intense competition from established pharmaceutical companies.
• Regulatory hurdles and FDA approval processes.
• Product liability claims.
• Limited financial resources and small market capitalization.
• OTC listing with associated liquidity and transparency concerns.

What Are the Growth Opportunities for NPHC?

• Expansion of the Nyloxin product line into new markets and applications represents a significant growth opportunity. The market for pain relief products is substantial, with a global market size estimated at billions of dollars. By targeting specific pain conditions and demographics, Nutra Pharma can capture a larger share of this market. The company's focus on non-narcotic pain relief alternatives aligns with the growing demand for safer pain management options.
• Development and commercialization of RPI-78M for neurological and autoimmune diseases could be a major growth driver. The market for treatments for conditions like multiple sclerosis and rheumatoid arthritis is substantial, with significant unmet medical needs. Successful clinical trials and regulatory approval could lead to substantial revenue growth for Nutra Pharma. This represents a high-risk, high-reward opportunity with a multi-year timeline.
• Leveraging the Pet Pain-Away product line to capitalize on the growing pet healthcare market. The pet healthcare market is experiencing rapid growth, driven by increased pet ownership and willingness to spend on pet health. By expanding the distribution channels and marketing efforts for Pet Pain-Away, Nutra Pharma can tap into this growing market. This represents a relatively low-risk growth opportunity with a shorter timeline.
• Strategic partnerships with pharmaceutical companies or distributors to expand the reach of Nutra Pharma's products. Collaborations with established players in the pharmaceutical industry can provide access to larger markets and distribution networks. This can accelerate the commercialization of Nutra Pharma's products and increase revenue growth. Identifying and securing suitable partners is crucial for realizing this growth opportunity.
• Expansion of the Luxury Feet product line into new retail channels and geographic markets. The market for foot care products is substantial, driven by the increasing awareness of foot health and the growing demand for specialized products. By expanding the distribution channels and marketing efforts for Luxury Feet, Nutra Pharma can tap into this growing market. This represents a relatively low-risk growth opportunity with a shorter timeline.

What Are NPHC's Competitive Advantages?

• Proprietary formulations for products like Nyloxin and Pet Pain-Away.
• Focus on niche markets with limited competition.
• Established brand recognition in specific product categories.
• Intellectual property rights for certain drug candidates.

What Does NPHC Do?

Nutra Pharma Corp., incorporated in 2000 and based in Plantation, Florida, is a biopharmaceutical company engaged in acquiring, licensing, and commercializing pharmaceutical products and technologies. The company focuses on homeopathic and ethical drugs aimed at managing pain, neurological disorders, cancer, and autoimmune and infectious diseases, primarily in the United States. Its key products include the Nyloxin line, featuring oral sprays and topical gels designed to alleviate pain associated with lower back issues, migraines, arthritis, and repetitive stress. The company also offers Pet Pain-Away, a homeopathic pain reliever for companion animals, and Luxury Feet, targeting pain from wearing high heels. Additionally, Nutra Pharma is developing RPI-78M for neurological and autoimmune diseases, RPI-MN for viral diseases including HIV/AIDS and herpes, and RPI-78 and RPI-70 for pain and arthritis. The company aims to provide alternative and effective treatments in areas with unmet medical needs.

What Products and Services Does NPHC Offer?

• Acquires and licenses pharmaceutical products and technologies.
• Commercializes homeopathic and ethical drugs.
• Develops treatments for pain management.
• Creates products for neurological disorders.
• Offers solutions for cancer and autoimmune diseases.
• Provides pain relief products for both humans and animals.

How Does NPHC Make Money?

• Acquires or licenses rights to pharmaceutical products and technologies.
• Manufactures and markets its own branded products, such as Nyloxin and Pet Pain-Away.
• Generates revenue through direct sales and distribution agreements.
• Focuses on niche markets within the pain management and neurological disorder sectors.

What Industry Does NPHC Operate In?

Nutra Pharma Corp. operates within the specialty and generic drug manufacturing industry, a segment characterized by intense competition and regulatory scrutiny. The market for pain management products is substantial, driven by an aging population and increasing prevalence of chronic conditions. Companies in this space must navigate complex FDA approval processes and compete with established pharmaceutical giants. Nutra Pharma's focus on homeopathic and niche products differentiates it from larger players, but also presents challenges in terms of market acceptance and scalability.

Who Are NPHC's Key Customers?

• Individuals seeking pain relief from conditions like arthritis, back pain, and migraines.
• Pet owners looking for homeopathic pain relief for their animals.
• Retailers and distributors who sell Nutra Pharma's products.
• The United States Military and Veteran's Administration through Nyloxin Military Strength.

Nutra Pharma Corp. Financial Trajectory

Nutra Pharma Corp. (NPHC) reported $34K in revenue for Q2 FY2026, a decline of 28.5% compared to the prior quarter. The company recorded a net loss of $3.9M, with diluted EPS of $-0.00. Revenue has contracted over three consecutive quarters, which investors in this unknown Healthcare stock should monitor closely. Across the four most recent quarters, NPHC averaged $-0.00 in diluted EPS.

Company Profile

Nutra Pharma Corp. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Boca Raton, US. The company is led by CEO Michael D. Flax. NPHC has traded publicly since 2001.

Return on equity for Nutra Pharma Corp. stands at 30.3%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.02 means current liabilities exceed short-term assets, a liquidity point worth watching.

Nutra Pharma Corp.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.

NPHC Financials

NPHC Latest News

NPHC Analyst Consensus

NPHC MoonshotScore

Nutra Pharma Corp. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources